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Abstract 
 
Initially, economic development increases resistance because migration of people to urban areas 
in developing countries increases incomes, crowding and the use of antibiotics. Also, developing 
countries often don’t require prescriptions or distribute high quality antibiotics. In developed 
countries, antibiotic resistance often falls or there is a decline in the rate of growth of resistance 
because infections decline with improvements in water quality, sanitation, housing and nutrition. 
However, in developed countries most antibiotics are used to treat food animals rather than 
humans. The use of antibiotics to treat food animals creates a risk that the effectiveness of 
antibiotics to treat humans will be reduced. However, evidence seems to indicate that antibiotic 
use in animals has had little effect on antibiotic resistance in humans.    
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Introduction 
 
The consequences [of antibiotic resistance] are severe.  Infections caused by resistant 
microbes fail to respond to treatment, resulting in prolonged illness and greater risk of 
death. Treatment failures also lead to longer periods of infectivity, which increase the 
numbers of infected people moving in the community and thus expose the general 
population to the risk of contracting a resistant strain of infection. (World Health 
Organization 2002). 
 
 This quotation illustrates the potential consequences of antibiotic resistance. Students are 
often interested in staying alive. Beyond the potential health consequences, antibiotic resistance 
is a useful way to teach how positive and negative externalities affect efficiency. Also, showing 
how economic development affects antibiotic resistance illustrates how the demand curve is 
affected by changes in income, the number of buyers, and insurance.   
 Externalities exist when either the benefits or costs of consumption or production spill 
over onto other people who did not agree to the action.  Antimicrobial use creates both negative 
and positive externalities (Coast et al. 1998 and Horowitz and Moehring 2004).  It creates a 
negative externality because antibiotics eliminate the less resistant bacteria while leaving the 
more resistant bacteria to multiply. These resistant microbes then infect others and reduce the 
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effectiveness of antimicrobials to them. This implies that the marginal costs incurred from a 
treatment include both the marginal cost of the treatment (MC) itself and the marginal external 
cost (MEC) from the resistant microbes. 
 Antimicrobial use creates a positive externality by reducing the number of infected 
people who in turn are less likely to infect others, thereby improving public health. This implies 
that the marginal benefit of treatment includes both the marginal benefit of treatment (MB) and 
the marginal external benefit from improved public health (MEB).   
 Efficient anti-microbial use occurs when the marginal benefit of treatment equals the 
marginal costs incurred from the treatment to both the person being treated and to others.  
Excessive antibiotics are used because users don't bear the full cost of treatment in the future.  
 Previous articles have explored how the negative externality from antibiotic resistance 
can be reduced by prevention and improved diagnosis (World Bank 1993), substitutes (Howard 
2004), property rights (Horowitz and Moehring 2004), taxation (Coast et al. 1998), regulation 
(Coast et al. 1998), tradeable permits (Coast et al. 1998), surveillance (Horan et al. 2008) and 
treaties (Anomaly 2010).  These articles, however, do not explore the effect of economic 
development on antibiotic resistance.   
Economic development has two contradictory effects on microbial resistance to 
antibiotics: First, economic development may increase resistance, since more people can afford 
antibiotics. A key determinate in antibiotic resistance is the volume of antibiotic exposure 
(Austin et al. 1999) such that countries that use more antibiotics tend to have more resistant 
bacteria (Bronzwaer et al., 2002 and Costelloe et al., 2010).  Second, economic development 
may reduce microbial resistance to antibiotics since countries can afford more effective infection 
control and better public health.  The reduction in disease reduces antibiotic use in humans and 
potentially microbial resistance. As countries develop, however, antibiotic resistance may 
increase as more antibiotics are used on animals. Hence, the effect of economic development on 
microbial resistance is ambiguous.  
Silbergeld et al.  (2008) argue that there are four reasons why antibiotic use in 
agricultural is a major cause for concern.  First, the largest use of antibiotics in the world is in 
agriculture. Second, much of the use of antibiotics in agriculture is sub-therapeutic exposure to 
antibiotics.  Third, every important class of antibiotic is used in agriculture.  And fourth, humans 
are exposed to resistant bacteria through consuming animal products and through release into the 
environment.  
However, reducing or restricting antibiotic use in agriculture may actually increase 
antibiotic resistance. This is because healthier animals are less likely to pass on resistant bacteria 
to humans. Singer et al. (2007) list three reasons why diseased animals increase foodborne 
pathogen levels.  First, diseased animals are more likely to spread pathogens. Second, diseased 
parts of diseased animals must be removed in processing plants which increases the risk of 
contamination and cross contamination. Third, diseased animals increase the risk that processing 
plant mistakes such as gastrointestinal ruptures will contaminate the meat from that animal and 
other animals. They conclude that small improvements in animal health may result in large 
improvements in human health. Likewise, Hurd et al. (2008) conclude that small improvements 
in animal health greatly reduce the risk of human sickness from foodborne illnesses.  
Alban et al. (2008), Hurd et al. (2008) and Hurd et al. (2004) conclude that reducing 
antibiotic use in animals leads to higher risk from illness from animals while the human risks 
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from antibiotic resistance from animals is very low. Cox et al. (2009) find that current penicillin 
use in food animals in the United States creates almost zero human health risks and Cox et al. 
(2004) find that a ban on Virginiamycin (VM) would have almost no benefit for human health.  
Cox et al. (2006) find that stopping animal antibiotic use would probably cause much more 
human illness than it would prevent. 
This article examines how economic development affects microbial resistance to 
antibiotics. Because many antimicrobials are used in animal husbandry, developed countries may 
use more antibiotics than developing countries.  However, human antibiotic use is likely to 
decline as the levels of human sickness decline. For simplicity, the analysis below assumes 
buyers purchase antibiotics solely for human use. 
 
How economic development affects the demand for antibiotics and efficiency 
 Suppose that the demand curve for a representative buyer is Pi = ai - bqi where qi 
measures the quantity of antibiotic treatments used by each buyer in country i, b is the slope of 
the demand curve, Pi is the price of an antibiotic treatment in country i, and ai is the maximum 
price that a buyer will spend on a antibiotic treatment in country i. 
 The buyer’s income and the price of substitutes determine ai. An increase in income or an 
increase in the price of a substitute will cause a parallel shift to the right in the demand curve.  
 Since government and private insurance programs pay much of the cost of many 
antibiotics, let si be the portion of the price paid by the buyer in country i (i.e. the buyer’s out-of-
pocket expenditure) so the buyer’s net price is siPi. 
 The demand curve for each individual buyer is: 
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 Let ni be the number of buyers. Multiplying qi in equation 1 by ni gives the total quantity 
of the antimicrobial used in country i (Qi) at a given price: 
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where Qi =  niqi.  Solving for Pi, the demand for the antimicrobial becomes: 
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MEBi is the marginal external benefit.  MEBi exists because antimicrobial use decreases the risk 
of infecting others.  One argument for a public health system is that  users of antimicrobials are 
unlikely to take into account the external benefits of antimicrobial use since the benefits go to 
other people.   
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 The marginal social benefit (MSBi) is the vertical summation of the MEBi and the demand 
curve:  
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When calculating the optimal price and quantity, subsidies and taxes are not included, thus si is 
not included in equation 4.  
 MCi is the marginal cost of an antibiotic treatment in country i.  MCi includes not only the 
price of the antibiotic but also the cost of visiting the doctor to get a prescription, the 
inconvenience and discomfort of complying with the treatment, and the availability and ease of 
access to health care facilities. When patients can purchase antibiotics without a prescription, the 
cost of visiting the doctor can be ignored and the marginal cost decreases. The lack of regulation 
on the quality of drugs and the dispensation of drugs is a major problem especially in developing 
countries (Okeke et al., 1999).  Also, the marginal cost decreases when there is easy access to 
nearby health care clinics and pharmacies (Walson et al. 2001).  
 A key determinate in antimicrobial resistance is the volume of antibiotic exposure 
(Austin et al. 1999; Levin et al. 2000; and Arason et al. 1996).  Countries that use more 
antibiotics tend to have more resistant bacteria (Bronzwaer et al., 2002 and Costelloe et al., 
2010).  This implies that the marginal external cost (MECi) increases with antimicrobial 
exposure.  When there is no antibiotic use, MEC is zero. As antibiotic use increases, MEC also 
increases. The marginal social cost (MSCi) is the vertical summation of the marginal cost and the 
marginal external cost i.e. MSCi = MCi + MECi.   
 This is illustrated in Figure 1.  With no intervention and multiple producers of the 
antibiotic, a competitive market will produce at point A with a price of P and Q treatments.  The 
efficient quantity of antimicrobial treatments is at point B where D+MEB=MC+MEC and is 
denoted Q* with a price of P*.   Current concern about antibiotic resistance implies that the MEC 
is much larger than the MEB.  Thus, antibiotic treatments are reduced in Figure 1.
3
   
 There are likely to be major disagreements on the optimal level of antibiotic treatment. 
The economically efficient level of antibiotics is probably greater than the medically efficient 
level (Rubin, 2004-2005). This is because calculations of medical efficiency may ignore the 
value that patients place on avoiding the costs from additional visits to the doctor when the 
diagnosis is uncertain. On the other hand, public health officials have an incentive to overstate 
the effects of resistance to gain access to more resources (Best, 2005).
4
 If public health officials 
overestimate the costs of resistance then they may try to reduce the level of treatments too much. 
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How economic development affects communicable diseases 
 Looking at diseases for which antibiotics are commonly prescribed, the burden of disease 
is about 61 times higher in low and middle income countries than in high income countries 
(Mathers et al. 2006).
5
 Since eighty-five percent of the world’s population lives in low and 
middle income countries (CIA World Factbook, 2006), adjusting for population, the burden of 
disease is about 11 times higher in low and middle income countries than in high income 
countries.
6
  In other words, high income countries have about 9.1% (1/11) of the disease burden 
that low and middle income countries have. 
  Part of the reason for more infections in the developing world is because of crowding in 
urban areas and lack of sanitation. Economic development is normally accompanied by internal 
migration and increased population density (Todaro, 1969). As people migrate to cities, 
microbial resistance to antibiotics may increase. This is because living in crowded unsanitary 
living conditions makes it easier to transmit resistant bacteria and people living in urban areas 
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countries into one category and calculate Disability-Adjusted Life Years (DALY) to quantify the global burden of 
disease.   
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usually have easier access to antibiotics.  Nys et al. (2004) found that in eight developing 
countries, faecal E. coli resistance was higher in urban populations than rural populations.  
 Throughout the world, urban areas gain approximately 67 million people per year or 
about 1.3 million per week (Meeting the Urban Challenge 2002). A major component of this 
increase is because rural people are attracted to cities in search of higher expected incomes 
(Todaro 1969, Meeting the Urban Challenge 2002).  Even though the average health of urban 
residents is higher than that of rural residents, the living conditions of the urban poor are worse 
than those of the urban non-poor and are often worse than conditions of the rural poor.  In 2005, 
31.2 percent of the world’s urban population lived in slums (State of the World’s Cities 2006/7); 
This represents more than a billion people. The urban poor who are especially at risk live in 
crowded conditions, with poor sanitation, and unsafe water.
7
  Polluted water and inadequate 
sanitation increase the probability of contracting diseases.
8
 
 This is analogous to nineteenth century America where internal migration caused as 
much as 50 percent of the increase in measured per capita income in the antebellum era (Fogel 
2004).  Internal migration, however, also was a major factor in spreading diseases such as 
cholera, typhoid, typhus, malaria, and dysentery (Smillie 1955 and Fogel 2004).  Increased 
density also increased the prevalence of malaria, enteric diseases, and diseases of the respiratory 
system (Smillie 1955, May 1958, and Fogel 2004).  
 As countries continue to develop, however, the number of microbial diseases falls 
dramatically.  For example, since the 18
th
 century, there has been a long-term decline in 
infectious disease mortality in developed countries (McKeown, 1976; Kunitz, 1991; Woods, 
1991; and Riley & Alter, 1989).  Reductions in infectious diseases increases the proportion of 
ingested energy available to work since less energy is used to mobilize the immune system 
(Dasgupta, 1993).  The capacity of the gut to absorb nutrients improves especially when there are 
fewer diarrheal diseases (Dasgupta, 1993).  The reduction in infectious diseases in developed 
countries was caused by improvements in nutrition, pasteurization, public hygiene, health care, 
vaccinations, and draining swamps (McKeown, 1976; Kunitz, 1991; Woods, 1991; Riley & 
Alter, 1989; Schofield and Reher, 1991; and Fogel, 2004).  
                                                 
7
  Households in developing countries often have limited access to improved sanitation and clean water 
supplies.  Fifty-four percent of households in low income countries and 41 percent in middle income countries did 
not have access to improved sanitation and 24 percent of households in low income countries and 19 percent in 
middle income countries did not have access to clean water sources in 2000 (World Development Indicators 2001).  
In developed countries, almost everyone had access to improved water sources and sanitation. 
8
  Cholera is mainly transmitted through contaminated food and water and is usually limited to developing 
countries where clean water and adequate sanitation are relatively scarce (Sack et al. 2001).  Shigellosis is primarily 
a disease of poor and crowded communities that do not have adequate sanitation or safe water (Sack et al. 2001).  In 
the developing world, shigellosis primarily infects children, with the urban poor being most affected.  Fatality rates 
are highest among children less than five years of age, especially those who are malnourished.  Most Campylobacter 
infections are through ingestion or handling of raw or inadequately prepared poultry, drinking raw milk, drinking 
contaminated water, and through fecal contact (Sack et al. 2001). There is also strong evidence that Campylobacter 
infections may be a major cause of Guillain-Barre syndrome (Allos, 1998).  In the United States, about 40 percent of 
Guillain-Barre Syndrome cases previously had Campylobacter infections (Altekruse et al. 1999). In developing 
countries, some cases of Guillain-Barre Syndrome probably were mis-diagnosed as polio. With the reduction in 
polio, many more cases of Guillian-Barre Syndrome will probably be diagnosed. Though, Campylobacter jejuni is 
the most common cause of diarrheal illness in the United States, Campylobacter infections are relatively rare in 
industrialized countries (Sack et al. 2001). 
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 Though developing countries have more infectious diseases than developed countries, 
following the Second World War, better nutrition, clean water supplies, improved sanitation, 
pasteurization, and vaccinations helped reduce infectious disease mortality in many developing 
countries (World Bank, 1993).  However, unlike the reduction in infectious diseases in the 
United States and Europe, medical interventions such as oral rehydration therapy, immunizations 
and antibiotics played a major role in reducing mortality in developing countries (Gwatkin, 1980; 
Hill and Pebley, 1989; and Ruzicka and Kane, 1990).  Still, in less affluent countries that lacked 
public health infrastructure, increased urbanization led to crowded unsanitary conditions that 
caused more communicable diseases (Mutatkar, 1995).  
 Many of these medical interventions were financed by foreign aid.  Foreign aid may have 
contradictory results on microbial resistance to antibiotics.  Programs that increase access to 
antibiotics either by establishing clinics or subsidizing antibiotic purchases tend to increase 
resistance.  For example, Walson et al. (2001) found that people who lived closer to clinics in 
Nepal had more resistant bacteria. On the other hand, programs that reduce microbial infections 
tend to reduce antibiotic use and thus resistance.   
 Gottret and Schieber (2006) note that foreign aid is often used to provide medical 
services to the non-poor even though it was intended to provide medical services to the poor.
9
 
Gottret and Schieber (2006) also note that the foreign aid received is too small given the disease 
burden. Also, the amounts they do receive are hard to administer because the country may 
receive large amounts of foreign aid one year, then a much smaller amount the next year. When 
donations are reduced, reallocating funds to cover the lost donations is difficult.  
 One of the most effective ways to reduce resistance is to prevent microbial infections. 
Preventing microbial infections reduces ni. Equation 3 shows that a reduction in ni rotates the 
demand curve toward the origin along the quantity axis, but does not change the price intercept. 
This decrease in ni can be shown in Figure 2 as a rotation from D to D’. Let D represent low and 
middle income countries and D’ represent high income countries. Since high income countries 
have about 9.1% of the infectious disease burden per capita that low and middle countries have, 
then ni=1 for demand curve D and ni=0.091 for demand curve D’.
10
 In Figure 2, the equilibrium 
number of antibiotic treatments for demand D is Q and the efficient quantity is Q*. The 
equilibrium quantity for demand D’ is Q’ and the efficient number of treatments is Q’*.  For ease 
of presentation, at Q’* the MEB=MEC so that Q’*=Q’. 
 
 
 
 
                                                 
9
  Foreign aid that is used to provide medical services to the non-poor even though it was intended to provide 
medical services to the poor is similar to a story told by Gordon Tullock where a fraudulent charity encourages 
people to help starving children. After collecting donations, the charity has professional actors pose in “before and 
after" photos showing the great benefits produced by the donations, and distributes the photos to the donors. This is 
Pareto optimal: the givers benefit, the charity becomes rich, and, assuming the donations were not diverted from a 
charity that would actually help the starving children, the real starving children are not hurt. When there is 
deception, Tullock argued that Pareto optimality can lead to policies that people would not support if they were 
better informed and exposing the fraud leads to the donors being worse off. 
10
  This assumes that people only buy antibiotic when they have an infectious disease and the only difference 
between high income countries and low and middle income countries is the number of buyers (ni). 
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The demand for an antibiotic can also be reduced by substituting other currently existing 
antibiotics, newly discovered antibiotics or other substances with antimicrobial properties such 
as plants like garlic (Ankri and Mirelman, 1999), phage therapy (McGrath and van Sinderen 
2007), sulfa drugs, or even anti-oxidants (Galley et al. 1997).
11
 However, unlike reducing 
microbial infections which rotates the demand curve in toward the origin, substitutes reduce ai in 
equation 3 which 
causes a parallel 
decrease in 
demand. 
Decreasing the 
demand for the 
antibiotic 
decreases the 
equilibrium 
quantity of the 
antibiotic and the 
equilibrium price.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How higher incomes and lower out-of-pocket expenditures affect the demand curve. 
 Figure 3 illustrates the effect of higher incomes for low (Dl), middle (Dm), and high (Dh)  
income countries.  Income increases dramatically as countries develop.
12
  In 1999, Gross 
National Income (GNI) per capita was $1,870 for poor countries, $5,200 for middle income 
countries, and $25,690 for high income countries (World Development Indicators, 2001).
13
 
                                                 
11
  Palaniappan and Holley (2010) find that natural antimicrobials may also have a synergistic effect with 
antibiotics by increasing the antibiotic susceptibility of drug resistant bacteria. 
12
  In each country, the antibiotic is assumed to be a normal good and b is assumed to equal 1.  Istúriz and 
Carbon (2000) report that in some low income countries per capita health expenditures are less than $10.  However, 
living standards in the low income country are probably understated because low income countries tend to have 
more home production, underground markets, and barter transactions. 
13
  These figures use purchasing power parity. 
D
Price
Quantity
MC
D+MEB
QQ*
P
B
A
C
MC+MEC
D’+MEB
D’
P*
P’* E
Figure 2
Prevention decreases the demand
for Anti-microbials 
P’
Q’=Q’*
66 | JOURNAL FOR ECONOMIC EDUCATORS, 14(1), SUMMER 2014 
 
 66 
Income per capita is about 178 percent (($5,200-$1,870)/$1,870) more in middle income 
countries than low income countries.  Income per capita in the high income countries is about 
394 percent (($25,690-$5,200)/$5,200) higher than in the middle income countries and 1274 
percent (($25,690-$1,870)/$1,870) higher than in the low income countries.  Baye et al. (1997) 
estimated 
that the 
income 
elasticity 
for anti-
infectives 
was about 
1.331. 
Holding 
everythin
g else 
constant, 
the GNI 
figures 
and the 
1.331 
income 
elasticity, 
imply that 
middle 
income 
countries 
will use 
237 
percent 
(1.78*1.3
31) more antimicrobials than low income countries and high income countries will use 1,696 
percent (12.74*1.331) more antimicrobials than low income countries.
14
 
 In the example in Figure 3, Dm and Dl are added to Figure 1 to illustrate how large an 
effect higher incomes along with the income elasticity can have on the demand for antibiotic 
treatments.
15
 With increasing incomes, consumers tend to decrease the percentage of their out-of-
                                                 
14
  These GNI and the income elasticity numbers may only apply to a specific period of time and thus may not 
be generalizable to other times or situations. 
15
  However, improvements in nutrition and physiology were major contributors to economic development.  In 
1790, people in the bottom 20 percent of caloric consumption in England and France probably did not have enough 
energy for sustained work and were thereby effectively excluded from the labor force (Fogel, 2004). Even those in 
the work force probably had only enough energy for limited amounts of work. Since then the number of calories 
available each day increased by about 50 percent (Fogel, 2004).  This increase in calories gave the bottom 20 
percent enough energy to enter the work force and increased the productivity of people already in the work force.  
Part of this increased productivity is because when people have better clothing and shelter there is less energy lost 
through the radiation of body heat (Dasgupta, 1993) and because the composition of diets shifted from grains and 
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pocket expenditures on health care (Gottret & Schieber 2006). In low income countries, more 
than 60 percent of health care expenditures are out-of-pocket. Out-of-pocket expenditures fall to 
40 percent in middle income countries and 20 percent in high income countries (Gottret & 
Schieber 2006).   
 Figure 4 shows the effect of lower out-of-pocket expenditures on the demand curve.  
D1.00 shows the previous demand curve where all expenses are paid by the purchaser of the 
antibitotic treatment.  D0.60 is for patients who pay 60% of the cost of their treatment, D0.40 is for 
patients who pay 40%, and D0.20 is for patients who pay 20% of their treatment.  The original 
equilibrium point is at A and the efficient output is a point B.  Now that people are receiving a 
subsidy to purchase the antibiotic the new equilibrium point is at C where people are willing to 
pay a higher price since someone else is paying and output is at Q’.  Lower out-of-pocket 
expenditures give people an incentive to consume more antibiotic treatments.  
When countries grow from low income to middle income countries, out-of-pocket health 
expenditures drop by 50 percent ((.4-.8)/.8).   When countries grow from middle to high income  
countries, there is a similar 50 percent ((.2-.4)/.4) drop in out-of-pocket health expenditures. As 
mentioned above, Baye et al (1997) calculated the uncompensated price elasticity of demand for 
anti-infectives to be about -0.916. Everything else constant, given the 50 percent reduction in 
out-of-pocket expenditures as a low income country develops to a middle income country, 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                             
other foods with high fiber content to meats and sugars with a higher proportion of ingested energy that could be 
metabolized (Fogel, 2004). Fogel (2004) estimates that this “thermodynamic” factor accounts for about 30 percent 
of the English growth rate since 1790. 
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         there may be nearly a 46 percent (-0.916*0.5) increase in antibiotic purchases and another 
46 percent (-0.916*0.5) increase in purchases as countries develop from middle income to high 
income countries.  
 Because of low incomes and high out-of-pocket expenditures, many poor patients in low 
income countries buy a small amount of an antibiotic and quit using it once symptoms disappear 
rather than after the treatment is complete (Okeke et al. 1999).
16
  Not completing a treatment 
may select for more resistant bacteria. 
 On the other hand, treatment guidelines may recommend long durations of treatment 
when short courses of treatment may not only be effective, but also reduce antibiotic exposure 
(Paul, 2006).  In mild to moderately severe cases of community acquired pneumonia, El 
Moussaoui et al. (2006) suggest that the appropriate duration of antibiotic treatment is three days 
rather than the recommended eight days.   
 Though economic development tends to decrease the percentage of people’s incomes 
spent on antibiotics, 
the effect of this 
decrease on 
microbial resistance 
to antibiotics is 
ambiguous.  If 
people in 
developed countries 
are more likely to 
complete antibiotic 
treatments, then 
economic 
development may 
reduce microbial 
resistance.  On the 
other hand, if 
people are more 
likely to consume 
antibiotics because 
the relative price 
falls, then 
economic 
development may 
increase microbial 
resistance. The next 
section discusses 
how higher 
incomes, lower out-
of-pocket spending and fewer communicable diseases affect human antibiotic use.   
                                                 
16
  This implies that policies that require patients to buy the full course of the antibiotic rather than by the 
tablet help reduce the premature stoppage of treatment.  
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How higher incomes, lower out-of-pocket spending, and fewer infections affect antibiotic 
treatments.  
 To estimate the magnitude of the effects of economic growth on the number of antibiotic 
treatments, consider how infections, out-of-pocket spending, and income affect the number of 
antibiotic treatments.  Column 2 in Table 1 shows that the high income countries have 9.1% of 
the infections of low and middle income countries. Column 3 shows that out-of-pocket spending 
is 60% the low income countries, 40% in the middle income countries, and 20% in the high 
income countries so sl=0.6, sm=0.4, and sh=0.2.  
 
 
 
Table 1 
How infections, out-of-pocket spending and income  
affect the demand for antibiotic treatments 
Country 
(1) 
n 
(2) 
s 
(3) 
a 
(4) 
High Income 0.091 0.2 16.96 
Middle Income 1 0.4 2.37 
Low income 1 0.6 1 
 
 
 As shown in Column 4, assuming antibiotics are normal goods, increasing income 
increases the demand for antibiotics. Holding everything else constant, higher incomes and the 
income elasticity of demand may cause middle income countries to demand 2.37 times more 
antibiotic treatments than low income countries and high income countries to demand 16.96 
times more treatments than in low income countries.
17
 
                                                 
17
  This assumes that the availability and prices of substitutes are equivalent in each country.   
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 Figure 5 
illustrates the net 
effects of higher 
incomes, lower 
out-of-pocket 
spending, and 
fewer people 
infected with 
microbial 
diseases.  
Assuming b=1, 
Dl is the demand 
curve for the low 
income country, 
Dm is the 
demand curve 
for the middle 
income country 
and Dh is the 
demand curve 
for the high 
income country.  
The middle 
income country 
has a larger 
demand (Dm) 
than the low income country (Dl), because people can afford to buy more antibiotics, the 
government has a larger budget to provide antibiotics, and out-of-pocket health expenditures 
decrease.The net effect on demand of developing from a middle income to a high income 
country is shown by shifting the demand curve from Dm to Dh.  There are two reasons for this 
shift.  First, the high income country has more than 10 times more income than the middle 
income country so ah is more than ten times larger than am and second, the high income country 
has less than a tenth of the infectious diseases of the middle income country so nh is less than a 
tenth of nm.  The increase in ai causes a parallel shift to the right of the demand curve and the 
decrease in ni causes the demand curve to rotate to the left but did not change the vertical price 
intercept.  
 In middle income and high income countries, the MC is likely to be lower than in low 
income countries because of improved storage and transportation systems. However, for 
simplicity in Figure 5, assume that the MC=$1 for each country.  
 These inferred demand curves and the assumed marginal cost curve imply that, at first, 
economic growth increases microbial treatments (Ql to Qm) and increases antibiotic resistance.
18
 
However, further economic growth (Qm to Qh) reduces antibiotic treatments.
19
   
                                                 
18
  The speculated increase from Ql to Qm is because of the number of infectious diseases in developing 
countries, the higher incomes in middle income countries than in low income countries and the lower out of pocket 
Price
Quantity
Dl
Dh
Dm
MC
Ql
Qh Qm
Figure 5
How Economic Growth Affects the
Demand for Anti-microbials 
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  In Figure 5, patent protection is likely to reduce antibiotic sales much more in the middle 
income country than in the high income country.  On the other hand, the price for patented 
antibiotics is likely to be much higher in the developed country than in the middle income 
country.  Since patented drugs are likely to be less available in developing countries, they are 
less likely to increase microbial resistance than generic drugs while microbial resistance against 
patented drugs is more likely to appear in richer countries.  
 Figure 6 compares the optimal level of antibiotic treatments with the quantities of 
antibiotics people wish to purchase.  Dl*, Dm*, and Dh* are the demand curves for the low, 
middle, and high income countries respectively when all expenditures for the antibiotic are out-
of-pocket (si=1).   
 
 
 
 The quote at the beginning of this article from the World Health Organization implies 
that antibiotic resistance has a significant effect on the optimal level of antibiotic treatments.
20
 
                                                                                                                                                             
expenses in the middle income countries.   
19
  The speculated decrease from Qm to Qh is mainly because the large decrease in infectious diseases reduces 
the demand for antibiotics.   
20
  According to Roberts et al. (2008) antibiotic dosing depends not only on the bacteria isolated but also the 
most resistant bacteria. Thus preventing further resistant infections may be achieved by increasing antibiotic 
exposure to the highest recommended dose. 
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MSC is chosen as representative of fairly large effects from antibiotic resistance. Assuming for 
simplicity that MEB=0, Ql*, Qm*, and Qh* are the optimal treatments for the low, middle and 
high income countries respectively.  The optimal number of treatments is highest for the high 
income country followed by the middle income country.  The low income country has the lowest 
amount of optimal treatments.  
 Figure 6 implies that countries with the greatest burden of disease would require the 
largest reductions in antibiotic use. However, withholding antibiotics from those most in need 
creates serious ethical issues. 
 
Evidence on Economic Growth and Microbial Resistance 
 A major issue with respect to microbial resistance is the scarcity of data, particularly 
from developing countries.
21
  The little available data are disease specific and under-represent 
developing countries.  Global studies include one or two developing countries or none at all.  
Combining data from different studies is problematic because the methodology is not 
standardized. 
 A global study that included some developing countries is Stelling et. al. (2005).  That 
study integrated Escherichia coli antimicrobial susceptibility data from multiple surveillance 
programs.  Table 2 shows 2001 non-susceptibility rates of Escherichia coli by income level.  
There are eighteen high income countries, eight upper-middle income countries, three lower-
middle-income economies, and zero low-income economies included in these calculations.
22
  As 
shown in column 1, Stelling et al (2005) present non-susceptibility rates for four antimicrobials: 
ampicillin, trimethoprim/sulfamethoxazole, ceftazidime, and ciprofloxacin.  The percentages in 
column 1 are the non-susceptible rates for each drug.  Lower percentages mean less microbial 
resistance. 
 For every drug in Table 2, as income increases, there is less microbial resistance.  
Consider resistance rates for ampicillin. In high income economies, 22% have non-susceptibility 
rates between 20-40%, 56% have non-susceptibility rates between 40-60%, and 22% have non-
susceptibility rates greater than 60%.  In upper-middle income economies, half have non-
susceptibility rates for ampicillin between 40-60% and half have non-susceptibility rates greater 
than 60%, while in lower-middle-income countries, all had non-susceptibility rates greater than 
60%.  Since no low-income countries were included, dashes represent the absence of data.   
 
 
 
 
 
 
                                                 
21
  Antimicrobial use data are much more unreliable than resistance data because of unofficial supply chains in 
developing countries that cannot be quantified. 
22
  Income classifications are based on World Bank definitions.  The high income countries include Australia, 
Belgium, Canada, Czech R., France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Singapore, Spain, 
Sweden, Switzerland, United Kingdom, and the United States.  High-middle-income countries include Argentina, 
Brazil, Chile, Mexico, Poland, South Africa, Turkey, and Venezuela.  Low-middle-income countries include 
Colombia, Philippines, and Thailand.  Taiwan was not included since the World Bank income categories don’t 
include Taiwan.  The data for Thailand only includes the drug Ceftazidime.   
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Table 2 
Non-susceptibility rates of Escherichia coli by income level, 2001* 
 
 Drug 
High-income 
econo
mies  
(18) 
Upper-middle income 
economies  
(8) 
Lower-middle-income 
economies 
 (3) 
Low-income 
econo
mies  
(0) 
Ampicillin     
  20-40% 22% 0% 0% - 
  40-60% 56% 50% 0% - 
  >60% 22% 50% 100% - 
Trimethorim/ 
sulfamethoxazole 
    
0-20% 17% 0% 0% - 
20-40% 56% 38% 0% - 
40-60% 28% 63% 100% - 
Ceftazidime     
≤5% 89% 63% 0% - 
>5% 11% 38% 100% - 
Ciprofloxacin     
≤10% 61% 40% 0% - 
>10% 39% 60% 100% - 
 *Authors’ calculations from Table 3 in Stelling et al (2005). 
 
Conclusion 
 Stelling et al. (2005) show that developing countries have more antibiotic resistance than 
developed countries. Three reasons why developing countries tend to have more resistance to 
antibiotics are: First, poverty and high out-of-pocket health expenditures in developing countries 
give consumers an incentive to purchase antibiotics in small quantities and stop treatment 
prematurely when their symptoms stop, thereby eliminating the less resistant bacteria while 
leaving the more resistant bacteria to multiply. Second, poverty and migration to cities increases 
the number of people living in crowded unsanitary conditions which increases infectious 
diseases. And third, people living in urban areas have easier access to antibiotics.    
 As economic development continues and incomes increase, infections decline with the 
advent of clean water supplies, effective sanitation systems, better public health, improved 
housing, better clothing, improved nutrition, pasteurization, vaccinations, drained swamps and 
better educated health care workers and consumers.
23
  Reducing infectious diseases increases the 
proportion of ingested energy available to work since less energy is used to mobilize the immune 
system and the capacity of the gut to absorb nutrients improves, especially when there are fewer 
diarrheal diseases.  The decline in infectious diseases creates a benefit to non-infected people 
since they are less likely to become infected.  As infections decline, fewer people use antibiotics 
and the growth rate of microbial resistance to antibiotics decreases.  
 
 
                                                 
23
  According to Easterlin et al (2011) economic growth causes people at first to migrate to cities because of 
the better living conditions but as countries continue to develop rural conditions improve. 
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